John H Strickler, Christel N Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E Uronis, S David Hsu, S Yousuf Zafar, Michael A Morse, David Z Chang, James L Wells, Kimberly L Blackwell, P Kelly Marcom, Christy Arrowood, Emily Bolch, Sherri Haley, Fatima A Rangwala, Ace J Hatch, Andrew B Nixon, Herbert I Hurwitz
BACKGROUND: Patients with chemotherapy refractory metastatic colorectal cancer (CRC) have a poor prognosis and limited therapeutic options. In this phase Ib/II clinical trial, we established the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) for the combination of capecitabine and ziv-aflibercept, and then we evaluated the efficacy of the combination in patients with chemotherapy refractory metastatic CRC. METHODS: All patients were required to have a Karnofsky Performance Status > 70% and adequate organ function...
November 1, 2019: BMC Cancer